APsense

  • Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis- Clinical Trials & Results, Patent, and Other Developments

The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation.

According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source.


According to the National Cancer Institute, the prevalence of cancer has been increasing at a very high rate. Therefore, companies are focusing on developing target specific and personalized medicine for the better treatment with reduced adverse events. Thus, NF-kB inhibitors therapeutics pipeline is likely to grow significantly, in the future, for the treatment of various diseases including cancer and chronic inflammation.

In May 2014, AnGes MG, Inc. and Shionogi & Co., Ltd. entered in a license agreement to co-develop NF-kB decoy oligodeoxynucleotide for the treatment of atopic dermatitis.
Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.

NF-kB Inhibitors Therapeutics Pipeline Analysis
·         By Phase
·         By Molecule Type
·         By Route of Administration
·         By Company


Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook


Share:

Oral Mucositis Therapeutics Pipeline Analysis - Clinical Trials, Results, Patent and Other Developments

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Oral mucositis is the most common complication of chemotherapy in cancer patients.

It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.




Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.



Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Dry Eye Syndrome Therapeutics Pipeline to Develop with Maximum Drugs Being Derived from Natural Sources

The study analyzed that the dry eyesyndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.


According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.




InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.


The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc.
Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.
Dry Eye Syndrome Therapeutics Pipeline Analysis
·         By Phase
·         By Route of Administration
·         By Molecule Type
·         By Company


Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Age-Related Macular Degeneration Therapeutics Pipeline Analysis-Clinical Trials & Results

According to a new research report “Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates.

The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.



As per the findings of the research, most of the drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route.



Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.


There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.

Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Candidiasis Therapeutics, Clinical Trials, Results & Pipeline Analysis


Candidiasis Therapeuticsd12


The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.

As per the findings of the research, most of the candidiasis drug candidates are being developed to be administered by oral route.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis/report-sample

Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=candidiasis-therapeutics-pipeline-analysis

The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia.
Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.
Candidiasis Therapeutics Pipeline Analysis
  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Amyotrophic Lateral Sclerosis (ALS) Pipeline Projects Vast Growth Ahead

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.
Amyotrophic Lateral Sclerosis Pipeline Analysis_12
The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan.
Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Analysis -Clinical Trials & Results, Patent, Designation, Collaboration

The study analysed that the PTSD pipeline comprises of 23 drug candidates in different stages of development. PTSD is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.




Many patents have been received during the development of drug candidates for the treatment of PTSD. In May 2017, Tonix reported the issuance of patent 9 636 408 by the United States Patent and Trademark Office titled “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the composition and manufacture of its proprietary sublingual formulation of very low dose cyclobenzaprine.



Significant growth in the therapeutic pipeline of PTSD is attributed to increasing collaboration between educational institutes, associations and pharma companies. Funds from the non-profit organizations have also been supporting the pipeline growth of PTSD therapeutics.


Some of the key players developing drugs for the treatment of PTSD include India Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies, Inc. and others.


Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook


Share:

Myasthenia Gravis Therapeutics Pipeline Analysis- Clinical Trials & Results, Patent, Designation, Collaboration

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myastheniagravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.
Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.
It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.
Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.
Myasthenia gravis Therapeutics Pipeline Analysis
·         By Phase
·         By Molecule Type
·         By Route of Administration

·         By Company
Share:

Technological Advancements to Lead the Process of Drug Development for the Treatment of Diabetic Foot Ulcer

The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where neuropathy dominates and neuroischemic foot where occlusive vascular disease is the main factor.


Diabetic neuropathy, peripheral artery disease and consequent trauma of the foot are the major risk factors for diabetic foot ulcer. The motor and sensory nerve damage can caus muscle weakness, paresis and atrophy in diabetic patients. Diabetic foot ulcer can be assessed by physical examination of the skin for the vascular, neurological, and musculoskeletal systems. Additionally, this examination also involves the assessment of perception of superficial pain, and temperature. Neuropathic disability score is assessed to evaluate the risk of occurrence of neuropathic ulceration.

Based on route of administration analysis of active drug candidates, it was found that around most of the drug candidates of diabetic foot ulcer pipeline are being developed to be administered by the topical route.
Most of the innovations in technology have been producing novel therapies for the treatment of diabetic foot ulcer. NOx is an advanced wound care technology invented by Edixomed Ltd, that provides the important moist environment, which aids in healing and absorbs wound exudate that generates nitric oxide.
Significant growth in the therapeutic pipeline of diabetic foot ulcer is attributed to increasing collaboration between educational institutes, associations and pharma companies as well as biotech companies. For instance, in March 2016, Microbion Corporation entered into an agreement with Haisco Pharmaceutical Group to develop and commercialize Microbion’s drug candidate for the treatment of chronic wounds in China and related territories.
Some of the key players developing drugs for the treatment of diabetic foot ulcer include Lakewood Amedex, Inc., Edixomed Ltd., CardioVascular BioTherapeutics Inc. and others.
Diabetic Foot Ulcer Pipeline Analysis
o    By Phase
o    By Route of Administration
o    By Molecule Type
o    By Company


Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook



Share:

Synovial Sarcoma Therapeutics Pipeline Analysis, Volume Analysis, Segments, Value Share and Key Trends


 The study analysed that the Synovialsarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.




Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.


The combination of novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.


The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

Synovial sarcoma Pipeline Analysis
·         By Phase
·         By Route of Administration
·         By Molecule Type
·         By Company


Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook

Synovial Sarcoma Exhibits Emerging Pipeline with 22 Drug Candidates

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect...
Share:

Popular Posts

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages